Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment?

Regarding the limited evidence for determining the optimal duration of antiviral treatment for hepatitis B, the long‐term outcome of patients with favorable responses to over 5 years of lamivudine monotherapy was investigated. Two hundred seventy‐one patients who had received lamivudine for at least 5 years were enrolled. Ultimately, 72 patients without YMDD mutations and showing hepatitis B virus (HBV) DNA levels